Trial · NCT01297309
Results by group36
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 36
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Event (TEAE) and Treatment Emergent Serious Adverse Event (TESAE) | rhPTH (1-84) | Number of participants with TESAE | 13 | Participants | |
| Number of Participants With Treatment Emergent Adverse Event (TEAE) and Treatment Emergent Serious Adverse Event (TESAE) | rhPTH (1-84) | Number of participants with TEAE | 48 | Participants | |
| Number of Responders With Calcium Source at Week 52 | rhPTH (1-84) | Citrate (Responder) | 7 | Participants | |
| Number of Responders With Calcium Source at Week 52 | rhPTH (1-84) | Carbonate (Responder) | 21 | Participants | |
| Number of Responders With Calcium Source at End Of Treatment (EOT) (Up to 82 Months) | rhPTH (1-84) | Citrate (Responder) | 7 | Participants | |
| Number of Responders With Calcium Source at End Of Treatment (EOT) (Up to 82 Months) | rhPTH (1-84) | Carbonate (Responder) | 20 | Participants | |
| Percent Change From Baseline in Oral Calcium Supplementation at Week 52 and EOT (Up to 82 Months) | rhPTH (1-84) | Percent change from baseline at Week 52 | -68.7 | Standard Deviation 34.07 | % change of oral calcium supplementation |
| Percent Change From Baseline in Oral Calcium Supplementation at Week 52 and EOT (Up to 82 Months) | rhPTH (1-84) | Percent change from baseline at EOT | -39.4 | Standard Deviation 107.23 | % change of oral calcium supplementation |
| Percent Change From Baseline in Oral Calcitriol Supplementation at Week 52 and EOT (Up to 82 Months) | rhPTH (1-84) | Percent change from baseline at Week 52 | -72.024 | Standard Deviation 44.6232 | %changeoforal calcitriol supplementation |
| Percent Change From Baseline in Oral Calcitriol Supplementation at Week 52 and EOT (Up to 82 Months) | rhPTH (1-84) | Percent change from baseline at EOT | -73.737 | Standard Deviation 39.3461 | %changeoforal calcitriol supplementation |
| Percent Change From Baseline in Albumin Corrected Total Serum Calcium (ACSC) at EOT (Up to 82 Months) | rhPTH (1-84) | -0.03 | Standard Deviation 0.190 | Percent change in ACSC | |
| Change From Baseline in 24-Hour Urine Calcium Excretion Through EOT (Up to 82 Months) | rhPTH (1-84) | Baseline | 8.92 | Standard Deviation 5.009 | Millimoles per day (mmol/day) |
| Change From Baseline in 24-Hour Urine Calcium Excretion Through EOT (Up to 82 Months) | rhPTH (1-84) | Change from Baseline at EOT | -2.37 | Standard Deviation 5.809 | Millimoles per day (mmol/day) |
| Change From Baseline in 24-hour Urine Calcium Excretion in Participants Who Used Calcium-Sparing Diuretics Through EOT (Up to 82 Months) | rhPTH (1-84) | EOT: Participants used calcium sparing diuretics | -4.07 | Standard Deviation 6.000 | Millimoles per day (mmol/day) |
| Change From Baseline in 24-hour Urine Calcium Excretion in Participants Who Used Calcium-Sparing Diuretics Through EOT (Up to 82 Months) | rhPTH (1-84) | EOT:Participants without calcium sparing diuretics | -1.79 | Standard Deviation 5.713 | Millimoles per day (mmol/day) |
| Change From Baseline in Serum Calcium Concentration in Participants Who Used and Calcium Sparing Diuretics at EOT (Upto 82 Months) | rhPTH (1-84) | EOT: Participants used calcium sparing diuretics | -0.21 | Standard Deviation 0.194 | Millimoles per liter (mmol/L) |
| Change From Baseline in Serum Calcium Concentration in Participants Who Used and Calcium Sparing Diuretics at EOT (Upto 82 Months) | rhPTH (1-84) | EOT:Participants without calcium sparing diuretics | -0.04 | Standard Deviation 0.200 | Millimoles per liter (mmol/L) |
| Change From Baseline in Serum Phosphate at Month 72 and EOT (Upto 82 Months) | rhPTH (1-84) | Change from Baseline at Month 72 | -0.309 | Standard Deviation 0.2280 | Millimoles per day (mmol/day) |
| Change From Baseline in Serum Phosphate at Month 72 and EOT (Upto 82 Months) | rhPTH (1-84) | Change from Baseline at EOT | -0.254 | Standard Deviation 0.2924 | Millimoles per day (mmol/day) |
| Number of Participants Who Maintained a Calcium Phosphate Product in A Normal Range at EOT (Up to 82 Months) | rhPTH (1-84) | 49 | Count of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01297309/results